1 day-1.98%
1 week-5.25%
Current month-5.92%
1 month-5.70%
3 months-0.75%
6 months-49.04%
Current year-60.26%
1 week 3,970
Extreme 3970
4,380
1 month 3,810
Extreme 3810
4,630
Current year 3,350
Extreme 3350
11,520
1 year 3,350
Extreme 3350
11,520
3 years 3,350
Extreme 3350
25,200
5 years 3,350
Extreme 3350
83,333.33
10 years 3,350
Extreme 3350
249,750
Manager TitleAgeSince
Chief Executive Officer 62 18/02/2010
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 18/02/2010
Director/Board Member 69 27/03/2024
Director/Board Member 63 27/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
15/04/25 Others 192,517 0.8373%
13/03/25 Buy

Chief Operating Officer

1,000 0.0043%
13/03/25 Buy

Founder

1,500 0.0065%
Change 5-day change 1-year change 3-year change Capi.($)
-1.98%-5.25%-56.71%-80.19% 71.1M
+0.88%-0.34%+40.64%+73.05% 64.69B
-0.26%+6.91%+11.14%+77.36% 54.78B
+0.47%+3.52%+8.22%+100.95% 53.49B
-2.06%+2.90%+24.07%+48.36% 45.98B
-1.79%+0.19%+19.32%+123.62% 42.94B
-1.65%+0.96%+237.56%+823.66% 40.08B
-2.26%-4.14%+15.38%+45.53% 33.52B
-2.40%-10.53%+20.12%-6.22% 23.97B
+12.10%+16.60%+55.14%+46.15% 23.67B
Average +0.10%+0.46%+37.49%+125.23% 38.32B
Weighted average by Cap. -0.05%+1.62%+45.50%+149.72%
Logo Vaxcell-Bio Therapeutics Co., Ltd.
VaxCell Biotherapeutics Co Ltd is a Korea-based company primarily engaged in the research and development of anticancer immunotherapeutic. The Company operates its business through three segments. The Anticancer Immunotherapy Business segment engages in the research and development of Vax-NK natural killer cell anticancer immunotherapy platform, Vax-DC dendritic cell anticancer immunotherapy platform, Vax-CAR series anticancer immunotherapy platform, and small molecule targeted anticancer drug platform. The Pharmaceutical and Medical Supplies Distribution Business segment engages in the wholesale business of pharmaceuticals and medical supplies and related pharmaceutical distribution business. The Companion Animal Healthcare Business segment engages in the manufacturing and sales of cytokine-based Vaxleukin-15 product, an anticancer immunotherapy for companion dogs.
Employees
-
Date Price Change Volume
26/10/26 ₩3,970.00 -1.98% 37,034
23/10/26 ₩4,050.00 -1.82% 40,447
22/10/26 ₩4,125.00 -2.83% 32,664
21/10/26 ₩4,245.00 -0.35% 47,516
20/10/26 ₩4,260.00 +1.67% 75,661
  1. Stock Market
  2. Stocks
  3. A323990 Stock